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Reactivation of HIV-1 proviruses in immune-compromised mice
engrafted with human VOA-negative CD4+ T cells
Zhe Yuan, Guobin Kang, Wuxun Lu and Qingsheng Li*
Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE,USA

Abstract
Background: HIV-1 infection remains incurable on antiretroviral therapy (ART) due to virus latency. To date, enhanced
co-culture assays, including viral outgrowth assays (VOA), are commonly used to measure HIV-1 latent reservoirs and
evaluate latency-reversing agents (LRAs). However, VOA can only reactivate a small fraction of intact proviruses.
Methods: To explore the utility of NOD scid gamma (NSG) mice as an in vivo model to reactivate HIV-1 proviruses from
VOA-negative CD4+ T cells, resting CD4+ T cells from an HIV-1 latently infected individual were isolated and the human
CD4+ T cells corresponding to VOA-positive and VOA-negative CD4+ T cells were engrafted into NSG mice. Plasma viral
load (pVL) and human CD4+ T cells were quantified every other week using qRT-PCR and flow cytometry.
Results: We found that NSG mice reactivated latently infected HIV-1 from VOA-positive CD4+ T cells as well as VOA-negative
CD4+ T cells. Engrafted CD4+ T cells proliferated considerably in vivo, peaked prior to provirus reactivation, and lasted for up
to 14 weeks. Sequence analyses revealed that reactivated proviruses in VOA-positive and VOA-negative CD4+T cells are different.
Conclusion: Taken together, NSG mice can support long-term engraftment of human CD4+ T cells and reactivate
VOA-positive and VOA-negative proviruses. Therefore, this in vivo model has the potential to be used to study the underlying
mechanisms of HIV-1 latency and reactivation.
Keywords: HIV-1 latency, viral outgrowth assay, immune-compromised mice, in vivo provirus reactivation, resting CD4+ T cells,
clonal expansion

Introduction
Remarkable progress has been made in reducing the mortality and
morbidity of HIV-1 infection through combined antiretroviral therapy
(ART); however, HIV-1 infection remains incurable due to virus
latency [1–3].To better understand the mechanisms of HIV-1 latency
and develop strategies to purge latent infection, quantitative in
vitro assays and in vivo animal models to study HIV-1 latency and
evaluate latency-reversing agents (LRAs) are critically needed. As
such, major quantitative assays, namely inverse PCR [4,5], improved
Alu PCR [6–8] and linker-primer PCR [9], have been previously
developed. Although these methods can quantify the frequency
of proviruses, they cannot distinguish between defective and
functional/intact proviruses, thus often overestimating the size
of the latent reservoirs. Enhanced co-culture assays, including
quantitative viral outgrowth assay (VOA), are frequently used in
quantifying functional proviruses [1,5]. It has been demonstrated
that less than 1% of proviruses can be reactivated to produce
infectious viruses after stimulation using VOA. It was also found
that the frequency of intact proviruses that cannot be reactivated
by VOA (VOA-negative intact proviruses) is at least 60-fold higher
than the frequency of induced proviruses by VOA (VOA-positive
intact proviruses) [10], indicating there is a population of intact
proviruses that is unmeasurable by VOA. A study compared the
reactivation properties of five in vitro primary T cell latency models
and four J-Lat cell latency models in response to 13 stimuli and
found that the in vitro model is not able to capture the ex vivo
reactivation properties of human infected cells [11]. Recently a
more sensitive Tat/rev induced limiting dilution assay (TILDA) was
developed to quantify the frequency of cells harbouring proviruses
by detecting tat/rev multiply-spliced HIV RNA upon in vitro
stimulation [12]. However, a new study showed that HIV-1 ‘defective’
proviruses are capable of transcribing and translating novel open
reading frames (ORFs), including the rev ORF [13], which further
complicated the measurement of functional proviruses using TILDA.
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The new generation of immune-compromised mice, such as NSG
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ Jackson Laboratory, Bar Harbor, Maine,
Stock number 005557), are excellent recipients for engrafting human
stem cells, cancer cells, lymphocytes, or even peripheral blood
mononuclear cells for biomedical research [14–17]. Recently, a report
showed that engrafting a large quantity of peripheral blood
mononuclear cells (PBMCs) (around 40 million per mouse) from HIV-1
infected patients into NSG mice can reactivate proviruses [18]. In
this work, the viraemia after engrafting can be detected up to 6
weeks, or shown to be transiently positive at 1 week post cell injection
(wpi). Nevertheless, it remains unknown whether xenograft can
reactivate HIV-1 provirus from VOA-negative CD4+T cells and whether
the in vivo model in this study can support HIV-1 viraemia long term
after solely engrafting human CD4+T cells.
To further explore the utility of NSG mice as an in vivo model to
quantify HIV-1 functional provirus and test whether this in vivo
method can be used to reactivate HIV-1 proviruses from VOAnegative CD4+ T cells, we engrafted NSG mice with a limited
quantity (2–3.6 million per mouse) of human resting CD4+ T cells.
We also included VOA-positive CD4+ T cells and resting CD4+ T
cells without VOA (uncultured CD4+ T cells) from an HIV-1
aviraemic patient under ART as a positive control.
We found NSG mice can reactivate not only latently infected HIV-1
from VOA-positive and uncultured CD4+ T cells, but also from
VOA-negative CD4+ T cells. Engrafted CD4+ T cells proliferated
considerably in vivo starting from 2 wpi and peaked prior to provirus
reactivation. The proliferation of engrafted CD4+ T cells in NSG mice
can support stable viraemia up to 14 weeks post engraftment.
Sequence analyses revealed that reactivated proviruses from
VOA-positive and VOA-negative CD4+ T cells are distinct from each
other, implying a difference in latency regulation. This study, for the
first time, demonstrates that NSG mouse engraftment can reactivate
intact proviruses from VOA-negative CD4+ T cells. This in vivo model
may be valuable to quantify the size of the HIV-1 latent reservoir
through serial dilution of a patient‘s resting CD4+T cells. Furthermore,
this method can be helpful to study the underlying mechanisms of
HIV-1 latency through amplification and long-term maintenance of
provirus reservoirs.
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Methods

Sequencing of reactivated viruses

Study subject

Viruses from the first pVL-positive samples were amplified using bulk
RT-PCR and sequenced.The cDNAs were amplified using Q5 Hot Start
High-Fidelity DNA Polymerase (New England Biolabs) with PCR primers:
forward 5’–TAGAGCCCTGGAAGCATCCAGGAAG-3’ and reverse
5’–TTGCTACTTGTGATTGCTCCATGT-3’.The amplicons were confirmed
by 1.0% agarose gel stained with ethidium bromide and bands were
cut and purified by GeneJET gel extraction kit (Thermo Scientific).
The amplicons of the 3kb spanning env region were sequenced using
Sanger‘s method at Sequetech (Mountain View, CA, USA) with eight
overlapping primers based on primer walking: F1 5’–TTAGGCATCTCCTAT
GGCAGGAAGAAG-3’, R1 5’-GTCTCGAGATACTGCTCCCACCC-3’, F2
5’-ATGATAC AGAGGTACATAATGTTTGG-3’, F3 5’-AAGTTGTAAC
ACCTCAGTCATTACAC-3’, F4 5’- GGAGATATGAGGG ACAATT-3’, F5
5’-GATTTGGGGTTGCTCTGGAAAACT CA-3’, F6 5’-AAGGAATAG
AAGAAGAAGGTGGAGAG-3’, and R2 5’-GTTCTACCATGTCATTT
TTCCACATG-3’.The sequencing results were manually examined peak
by peak and the ends of sequences containing ambiguous nucleotides
were trimmed.The sequences were confirmed by overlapping identical
regions. Then the sequences were assembled individually to obtain
the 3-kb partial genome using Sequencher 5.0 (Gene Codes Corporation
Ann Arbor, MI, USA). A phylogenetic tree containing the assembled
virus sequences and a HXB-2 homolog region reference sequence
was generated using MUSCLE 3.8 [20] and PHYML 3.0 [21] through
the maximum likelihood method and displayed with FigTree 1.4.2
(http://tree.bio.ed.ac.uk/software/figtree/).

PBMCs were obtained from an HIV-1 infected individual, who had
14.3 years of diagnosed infection and continuous suppression of
plasma HIV-1 with ART (emtricitabine-tenofovir, ritonavir and
atazanavir) at undetectable levels (<50 copies/mL) for 6.3 years
prior to sampling time. The CD4 cell count was 627 cells/mm3 at
the time of this study. The infected donor exhibited 0.518 infectious
units per million (IUPM). This study was approved by the Johns
Hopkins Institutional Review Board, written informed consent was
obtained from all participants as per a previous report [10].

Human resting CD4+ T cell isolation and
virus outgrowth assay
Resting CD4+ T cells were isolated from the PBMCs of the HIV-1
aviraemic individual by negative selection using the CD4+ T Isolation
Kit II with CD25, CD69 and HLA-DR microbeads (Miltenyi Biotec,
San Diego, CA, USA) [1,10]. Some of the resting CD4+ T cells were
cryopreserved immediately, using liquid nitrogen, as an uncultured
control; the remaining cells were clonally expanded using a previously
published protocol [10] and divided into equal portions for VOA and
mouse engraftment, respectively. Cells engrafted into mice were grouped
based on the VOA results into VOA-positive and VOA-negative groups.

NSG mice
Six-week old female NSG mice were maintained in micro-isolator
cages within BSL-2 animal rooms following the protocol approved
by the Institutional Animal Care and Use Committee at the
University of Nebraska-Lincoln. Cryopreserved cells corresponding
to VOA-negative CD4+ T cells (P46N) with VOA-positive (P46P)
and uncultured (P46U) controls were thawed at 37°C and washed
once using culture medium containing 100 U/mL IL-2. Cell viability
was checked using a Vi-Cell XR cell viability analyzer (Beckman
Coulter, Indianapolis, IN, USA); cells were resuspended into 200 μL
of culture medium and injected into a mouse via a tail vein. Plasma
viral load (pVL) and peripheral blood CD4+ T cells were quantified
using qRT-PCR and flow cytometry, respectively, every 2 weeks.

Plasma viral load quantification
Viral RNA was extracted from plasma using QIAamp Viral RNA Mini
kit (Qiagen, Valencia, CA, USA). pVL was determined by qRT-PCR,
wherein cDNA was synthesised using Superscript III Reverse
Transcriptase, RNaseOUT and RNase H (Life Technologies, Grand
Island, NY, USA) with the gene specific primer: 5’-TTGCTAC
TTGTGATTGCTCCATGT-3’. The qPCR was run on C1000 Thermal
Cycler and CFX96 Real-Time system (Bio-Rad) using TaqMan Fast
Virus 1-Step Master Mix (Life Technologies, Grand Island, NY) with
primers: forward 5’-GCCTCAATAAAGCTTGCCTTGA-3’, reverse
5’-GGGCGCCACTGCTAGAGA-3’ and probe: 5’-/56-FAM/
CCAGAGTCA/ZEN/CACAACAGACGGGC ACA/3IABkFQ/-3’. The
detection limit of plasma HIV-1 RNA was 200 copies/mL and was
determined through repeating endpoint detection from serial
dilution of the AcroMetrix HIV-1 Panel (Life Technologies) [19].

Flow cytometry
Human CD4+ T cells isolated from mouse peripheral blood were
measured using FACS Aria II flow cytometer (BD Biosciences, San
Jose, CA, USA) after staining with antibodies against human CD45
(FITC conjugated; clone# HI30, BioLegend, San Diego, CA, USA),
human CD3 (PE conjugated, clone# HIT3a, BioLegend), and human
CD4 (Alexa Fluor 700 conjugated, clone# OKT4, BioLegend). Cells
were blocked using Human TruStain FcX and Mouse TruStain fcX
Antibodies (BioLegend) prior to staining. Raw data were analysed
with FlowJo version 10.0 (FlowJo LLC, Ashland, OR, USA).
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HIV-1 sequences obtained from this study have been deposited
into GenBank under accession number KT223503, KT223504 and
KT223505.

Results
Xenograft of human CD4+T cells into NSG mice reactivated
the proviruses from VOA-positive and VOA-negative samples
First, we wanted to test whether NSG mice engrafted withVOA-negative
CD4+T cells could reactivate proviruses.To compare in vivo NSG mouse
reactivation of provirus with VOA, CD4+ T cells were first expanded
in vitro and split into two equal portions before VOA. One portion
was immediately cryopreserved for NSG mouse engraftment and the
other portion was used for VOA serving as a surrogate for reactivation
of the corresponding cryopreserved cells (Figure 1). After 3 weeks of
VOA culture, HIV-1 p24 in the supernatant of each well was quantified
using ELISA.The cryopreserved cells corresponding to the VOA-positive
and the VOA-negative samples and uncultured positive control were
injected into NSG mice via the tail vein. Plasma vRNA was quantified
using qRT-PCR every other week.
Plasma viral RNA load was detectable at 4 wpi in both the
VOA-positive (P46P, Figure 2A) and the uncultured sample (P46U,
data not shown) as positive control. The pVL was undetectable
at 2 wpi, became positive at 4 wpi (6.06 × 105 copies/mL), and
then remained at a plateau until the animal was euthanised at
14 wpi. In contrast, the pVL in the P46N engrafted mouse was
undetectable before and at 8 wpi, became positive at 10 wpi
(4.78 × 105 copies/mL) (Figure 2B), and remained at a plateau
until the animal was euthanised at 14 wpi.

Human CD4+T cells engrafted in NSG mice can proliferate
and support stable viraemia for a long time
We then checked whether immune-compromised NSG mice can
maintain engrafted human CD4+ T cells for a long term using flow
cytometry. As shown in Figure 2, we found that engrafted CD4+ T
cells proliferated considerably in vivo starting from 2 wpi and peaked
before the provirus was reactivated (4 wpi for P46P and P46U, and
10 wpi for P46N). Upon provirus reactivation, CD4+T cells significantly
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Figure 1. Experimental design. Resting CD4+ T cells were isolated from an HIV-1 aviraemic individual on ART. After clonal expansion, CD4+ T cells were split into equal parts for
cryopreservation and VOA. Cryopreserved cells corresponding to VOA-positive wells (P46P), VOA-negative wells (P46N), and uncultured resting CD4+ T cells (P46U), were
thawed and intravenously injected into NSG mice respectively. Plasma viral load (pVL) and peripheral blood CD4+ T cells were measured every other week using qRT-PCR and
flow cytometry. HIV-1 env sequences from the first pVL positive samples were sequenced using Sanger‘s method.

Figure 2. Kinetics of provirus reactivation and human CD4+ T cell quantification in NSG mouse engrafted with VOA-negative resting CD4+ T cells with positive control.
(A) Cryopreserved cells corresponding to VOA-positive well (P46P) were intravenously injected into NSG mouse and (B) VOA-negative well (P46N). Arrows indicate the first
time that pVL became positive and the samples for sequencing.

declined (Figures 2 and 3). Of note, active proliferation of CD4+T
cells (4 and 6 wpi) in the VOA-negative sample was several weeks
ahead of pVL detection (Figure 3B).This temporal difference between
CD4+ T cell proliferation and provirus reactivation indicates cell
proliferation alone is not sufficient to reactivate provirus, and cell
proliferation and provirus reactivation are independent events.

Reactivated proviruses from VOA-positive and VOA-negative
CD4+ T cells were heterogeneous
To determine whether the reactivated proviruses from VOA-positive
and VOA-negative CD4+ T cells were identical, a 3-kb HIV-1 partial
genome spanning the full-length env from the first viraemic plasma
samples was amplified using qRT-PCR and sequenced using
Sanger‘s method. The sequences of each sample are homogeneous
with a pure single peak for every position. However, for different
samples, the reactivated HIV-1 proviruses were heterogeneous
(Figure 4A) and contained different in-frame insertions compared
to the reference HXB2 sequence (Figure 4B).

Discussion
Curing HIV-1 infection by eradicating virus latency is one of the
highest public health priorities. Enhanced co-culture assays,
including VOA, have greatly deepened our understanding of HIV-1
latency; however, VOA can only reactivate a small fraction of intact
proviruses. Thus, the underlying mechanisms of HIV-1 latency are
not completely understood.
This study for the first time shows that engraftment of VOA-negative
CD4+ T cells into NSG mice can reactivate proviruses. The results
herein also demonstrate that HIV-1 latently infected CD4+ T cells

engrafted into NSG mice can proliferate and survive for up to 14
weeks, which provides a prolonged window of opportunity to study
HIV-1 latency and its reactivation. While VOA-positive CD4+ T cells
and uncultured cells engrafted into NSG mice reactivated latent HIV-1
at 4 wpi, VOA-negative CD4+ T cells reactivated latent HIV-1 at 10
wpi. This delayed reactivation may mirror the delayed HIV-1 rebound
after cessation of ART in HIV-1 functional controllers mediated through
early initiation of ART in the ‘Mississippi child’ [22] and the ANRS
VISCONTI study [23], as well as in the ‘Boston patients’ mediated
through allogenic bone marrow stem cell transplant [24].The delayed
reactivation observed in the VOA-negative CD4+ T cells in this study
supports the notion of heterogeneity of latently infected HIV-1 in
resting CD4+ T cells [25,26]. The distinct sequences of reactivated
proviruses from VOA-positive and VOA-negative CD4+T cells indicate
that there are different intact proviruses in resting CD4+ T cells with
different reactivation efficiency.
Our study has demonstrated that provirus from engrafted human
VOA-negative CD4+T cells can be reactivated. A plausible explanation
is that engrafted human CD4+ T cells underwent proliferation and
expansion as shown in Figure 3, which might increase the quantity
of provirus-bearing cells; meanwhile xeno-immune activation might
also contribute to the reactivation of proviruses. However, the exact
mechanism of provirus reactivation in this system remains to be studied.
The temporal difference between the engrafted CD4+T cell expansion
and provirus reactivation indicates that cell proliferation does not
directly reactivate provirus. Furthermore, the sequencing results
revealed that the reactivated proviruses from VOA-negative and
VOA-positive CD4+ T cells were different, indicating that latency
reactivation regulation maybe different.
Provirus reactivation in VOA-negative CD4+ T cells
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Figure 3. Kinetics of human peripheral blood CD4+ T cells in engrafted NSG mice. (A) The NSG mouse was engrafted with cryopreserved VOA-positive (P46P) as a control. (B) The NSG
mouse was engrafted with VOA-negative sample (P46N).

We would like to point out the limitation of this case study. We
operationally called cryopreserved cells corresponding to VOApositive/negative cells; however, it is likely the split portions
contained clonally expanded cells. Future studies that include more
cases with determined clonality of engrafted cells by integration
site sequencing analyses will be needed.
Collectively, this study clearly demonstrates that NSG mice can
support long-term engraftment of human CD4+ T cells and
reactivate proviruses from VOA-negative CD4+ T cells, which not
only provide a large window for studying the HIV-1 latency at
molecular and cellular detail, but can also be used to quantify the
functional latent reservoir.
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Figure 4. Sequencing results for reactivated HIV-1 from VOA-positive, VOA-negative and uncultured resting CD4+ T cells engrafted into NSG mice. (A) Phylogenetic relationship of
reactivated HIV-1 from VOA-positive provirus, VOA-negative provirus, and uncultured resting CD4+ T cells using HXB2 as the reference sequence. (B) A representative region
showing the differences between the reactivated viruses from VOA-positive, VOA-negative and uncultured sample contains different in-frame insertions as compared to the
reference HXB2 sequence.
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